Skip to content

Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing, a First in Human Trial

Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing, a First in Human Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02670460
Enrollment
24
Registered
2016-02-01
Start date
2015-10-31
Completion date
2016-04-30
Last updated
2016-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventilator Induced Lung Injury

Brief summary

Study conducted to confirm phrenic nerve stimulation using the Lungpacer LIVE Catheter, confirm capture of the diaphragm and confirm that the diaphragm can be paced in synchrony with mechanical ventilator breaths.

Detailed description

This study is being conducted to determine if in an anaesthetized (sedated, intubated and mechanically ventilated) subject the LIVE Catheter can be inserted percutaneously and activated via the electrical stimulator to stimulate the left and right phrenic nerves causing the diaphragm to contract in synchrony with mechanical ventilator breaths via phrenic nerve stimulation from a transvenously delivered electrical current.

Interventions

Placement of a temporary LIVE Catheter central venous pacing device in the left subclavian vein to pace the phrenic nerves and allow recruitment of the diaphragm muscle.

Sponsors

Lungpacer Medical Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Able and willing to give informed consent or whose legally authorized representative is able and willing to give informed consent. * Able to undergo general anaesthesia (sedation, intubation and mechanical ventilation) * Susceptible indication for atrial septal defect closure

Exclusion criteria

* Subject has an EF of \< 30% * Subject has a co-morbid illness or life expectancy \< 2 years * Subject has experienced an AMI within 72 hours prior to this procedure * Subject is contraindicated for or unwilling to take aspirin or anticoagulants * Subject is in cardiogenic shock * Subject has other cardiovascular disease requiring open heart surgery * Subject is known to have a demonstrated intra cardiac thrombus on echocardiography * Subject has been treated with paralytic medications within 72 hours prior to procedure * Subject has significant thoracic abnormalities such that placement of a left subclavian line would be difficult * Inability to cannulate the left subclavian vein (post-consent exclusion) * Subject has a known or suspected phrenic nerve paralysis * Subject has co-existing temporary or implanted cardiac electrical devices such as a pacemaker or defibrillator * Subject has an active systemic infection or local infection at or around the insertion site * Subject is known or suspected to be pregnant or is lactating * Subject will be unavailable for, or is unwilling to comply with, follow up requirements of the protocol * Subject is currently enrolled in any other study of an investigational drug or device who has received treatment under that protocol with the investigational product during the 30 days prior to screening.

Design outcomes

Primary

MeasureTime frameDescription
Successful insertion of the LIVE Catheter into the left subclavian vienat time of procedureConfirmation by cinefluoroscopy of the insertion of the LIVE Catheter into the Left subclavian vein with the tip located in the superior vena cava
Absence of device related or procedure related adverse eventsup to 48 hours or at time of discharge whichever comes firstAssess subject AE status out to 48 hours post procedure

Secondary

MeasureTime frameDescription
Phrenic nerve stimulation in synchrony with MV breathsNo more than 90 minutes procedure durationPhrenic nerve stimulation in synchrony with MV breaths as defined by contraction of the diaphragm upon energy delivery.

Countries

Paraguay

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026